Can Editas, BeiGene Offerings Redeem US IPO Class Of 2015?
This article was originally published in Scrip
Executive Summary
US initial public offerings by biotechnology companies in 2015 dried up in November, but since Editas Medicine Inc. and BeiGene Ltd. had strong offerings to kick off February, does that mean that dozens of drug developers will be able to go public again in 2016?
You may also be interested in...
SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.
SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.
Finance Watch: One Week Of IPOs Total $818.2m
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.